Logo image of VIVO

MERIDIAN BIOSCIENCE INC (VIVO) Stock Fundamental Analysis

NASDAQ:VIVO - Nasdaq - US5895841014 - Common Stock - Currency: USD

33.97  0 (0%)

After market: 33.99 +0.02 (+0.06%)

Fundamental Rating

6

VIVO gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making VIVO a very profitable company, without any liquidiy or solvency issues. VIVO has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year VIVO was profitable.
VIVO had a positive operating cash flow in the past year.
VIVO had positive earnings in each of the past 5 years.
Each year in the past 5 years VIVO had a positive operating cash flow.
VIVO Yearly Net Income VS EBIT VS OCF VS FCFVIVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

1.2 Ratios

VIVO's Return On Assets of 9.17% is amongst the best of the industry. VIVO outperforms 88.89% of its industry peers.
VIVO's Return On Equity of 11.54% is amongst the best of the industry. VIVO outperforms 87.50% of its industry peers.
VIVO's Return On Invested Capital of 14.66% is amongst the best of the industry. VIVO outperforms 94.44% of its industry peers.
The Average Return On Invested Capital over the past 3 years for VIVO is significantly above the industry average of 7.87%.
The last Return On Invested Capital (14.66%) for VIVO is well below the 3 year average (49.65%), which needs to be investigated, but indicates that VIVO had better years and this may not be a problem.
Industry RankSector Rank
ROA 9.17%
ROE 11.54%
ROIC 14.66%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
VIVO Yearly ROA, ROE, ROICVIVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 5 10 15 20 25

1.3 Margins

VIVO has a better Profit Margin (12.75%) than 87.04% of its industry peers.
In the last couple of years the Profit Margin of VIVO has grown nicely.
VIVO's Operating Margin of 22.70% is amongst the best of the industry. VIVO outperforms 93.52% of its industry peers.
In the last couple of years the Operating Margin of VIVO has remained more or less at the same level.
VIVO's Gross Margin of 56.56% is in line compared to the rest of the industry. VIVO outperforms 55.56% of its industry peers.
VIVO's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 22.7%
PM (TTM) 12.75%
GM 56.56%
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
VIVO Yearly Profit, Operating, Gross MarginsVIVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VIVO is creating value.
VIVO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for VIVO has been reduced compared to a year ago.
VIVO Yearly Shares OutstandingVIVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
VIVO Yearly Total Debt VS Total AssetsVIVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

VIVO has an Altman-Z score of 11.77. This indicates that VIVO is financially healthy and has little risk of bankruptcy at the moment.
VIVO has a Altman-Z score of 11.77. This is amongst the best in the industry. VIVO outperforms 88.89% of its industry peers.
VIVO has a debt to FCF ratio of 0.34. This is a very positive value and a sign of high solvency as it would only need 0.34 years to pay back of all of its debts.
VIVO's Debt to FCF ratio of 0.34 is amongst the best of the industry. VIVO outperforms 93.52% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that VIVO is not too dependend on debt financing.
VIVO has a Debt to Equity ratio (0.07) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.34
Altman-Z 11.77
ROIC/WACC1.53
WACC9.57%
VIVO Yearly LT Debt VS Equity VS FCFVIVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.63 indicates that VIVO has no problem at all paying its short term obligations.
VIVO's Current ratio of 3.63 is in line compared to the rest of the industry. VIVO outperforms 50.00% of its industry peers.
VIVO has a Quick Ratio of 2.46. This indicates that VIVO is financially healthy and has no problem in meeting its short term obligations.
VIVO has a Quick ratio of 2.46. This is comparable to the rest of the industry: VIVO outperforms 45.83% of its industry peers.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 2.46
VIVO Yearly Current Assets VS Current LiabilitesVIVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

VIVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.86%.
Measured over the past years, VIVO shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.21% on average per year.
The Revenue has been growing slightly by 4.76% in the past year.
VIVO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.65% yearly.
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIVO Yearly Revenue VS EstimatesVIVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M
VIVO Yearly EPS VS EstimatesVIVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0.5 1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 24.62, VIVO is valued on the expensive side.
Based on the Price/Earnings ratio, VIVO is valued cheaply inside the industry as 83.80% of the companies are valued more expensively.
VIVO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.60, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 40.37, the valuation of VIVO can be described as expensive.
Based on the Price/Forward Earnings ratio, VIVO is valued a bit cheaper than the industry average as 75.93% of the companies are valued more expensively.
VIVO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.43.
Industry RankSector Rank
PE 24.62
Fwd PE 40.37
VIVO Price Earnings VS Forward Price EarningsVIVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

VIVO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VIVO is cheaper than 86.57% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, VIVO is valued cheaply inside the industry as 94.44% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 20.27
EV/EBITDA 15.62
VIVO Per share dataVIVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

VIVO has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.62
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VIVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERIDIAN BIOSCIENCE INC

NASDAQ:VIVO (1/30/2023, 8:27:46 PM)

After market: 33.99 +0.02 (+0.06%)

33.97

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-26 2023-01-26/amc
Earnings (Next)05-04 2023-05-04/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners2.73%
Ins Owner Change0%
Market Cap1.49B
Analysts43.33
Price Target34.68 (2.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.65%
Min EPS beat(2)-1.96%
Max EPS beat(2)37.25%
EPS beat(4)3
Avg EPS beat(4)27.19%
Min EPS beat(4)-1.96%
Max EPS beat(4)37.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.54%
Min Revenue beat(2)-4.52%
Max Revenue beat(2)-0.56%
Revenue beat(4)2
Avg Revenue beat(4)6.92%
Min Revenue beat(4)-4.52%
Max Revenue beat(4)23.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.21%
Valuation
Industry RankSector Rank
PE 24.62
Fwd PE 40.37
P/S 4.49
P/FCF 20.27
P/OCF 18.15
P/B 4.06
P/tB 8.42
EV/EBITDA 15.62
EPS(TTM)1.38
EY4.06%
EPS(NY)0.84
Fwd EY2.48%
FCF(TTM)1.68
FCFY4.93%
OCF(TTM)1.87
OCFY5.51%
SpS7.57
BVpS8.36
TBVpS4.04
PEG (NY)N/A
PEG (5Y)1.62
Profitability
Industry RankSector Rank
ROA 9.17%
ROE 11.54%
ROCE N/A
ROIC 14.66%
ROICexc 18.35%
ROICexgc 44.57%
OM 22.7%
PM (TTM) 12.75%
GM 56.56%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
ROICexc(3y)19.62%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y10.61%
ROICexcg growth 5Y2.24%
ROICexc growth 3Y13.29%
ROICexc growth 5Y-2.41%
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
F-Score5
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.34
Debt/EBITDA 0.27
Cap/Depr 52.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 173.69%
Current Ratio 3.63
Quick Ratio 2.46
Altman-Z 11.77
F-Score5
WACC9.57%
ROIC/WACC1.53
Cap/Depr(3y)65.44%
Cap/Depr(5y)57.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)112.8%
Profit Quality(5y)119.92%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.75%
EBIT growth 3Y24.79%
EBIT growth 5Y11.03%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.89%
FCF growth 3Y31.57%
FCF growth 5Y14.86%
OCF growth 1Y23.18%
OCF growth 3Y31.55%
OCF growth 5Y14.77%